Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Liposom Forte plus citalopram vs placebo in elderly MDD
2024-512293-10-00Phase 4Authorised
- Sponsor
- Fidia Farmaceutici
- Start
- Nov 2024
- Modality
- Liposomes → Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in major depressive disorder (MDD) comparing Citalopram + Liposom Forte with Citalopram + placebo (2 arms). Primary endpoint: Change in depressive symptoms at Day 30 by HAM-D. Planned start Nov 2024; status: authorised.
02
Drugs
hypothalamic phospholipid liposomes
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on 2024-512293-10-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-512293-10-00.